What is the expected growth forecast for the Implantable Contraceptive Drug Eluting Devices market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Implantable Contraceptive Drug Eluting Devices market?

Increasing demand for long-acting reversible contraceptives drives the market.

Which regions are leading the Implantable Contraceptive Drug Eluting Devices market?

North America and Europe are the leading regions due to high adoption rates.

Who are the top companies in the Implantable Contraceptive Drug Eluting Devices market?

Major players include Bayer and Merck, offering a range of contraceptive products.

What future opportunities exist in the Implantable Contraceptive Drug Eluting Devices market?

Emerging markets and innovative products offer growth opportunities.

How will technology impact the Implantable Contraceptive Drug Eluting Devices market?

Advances in material science and drug delivery systems will drive innovation.

What is the current regulatory landscape for the Implantable Contraceptive Drug Eluting Devices market?

Regulatory bodies such as the FDA and EMA oversee the approval of devices.

Why Is the Implantable Contraceptive Drug Eluting Devices Market Growing So Fast? 2026 Analysis

Implantable Contraceptive Drug Eluting Devices by Application (Subcutaneously, Uterus), by Types (Non-biodegradable, Biodegradable), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 143

Forecast Period: 2026 - 2033

Market Size: $4319 million

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 143

Forecast Period: 2026 - 2033

Market Size: $4319 million

CAGR: 3.9%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Implantable Contraceptive Drug Eluting Devices Market Overview

The Implantable Contraceptive Drug Eluting Devices market refers to the industry segment focused on developing and marketing implantable devices that release contraceptive drugs to prevent pregnancy. As the Implantable Contraceptive Drug Eluting Devices market size is expected to witness significant growth, driven by increasing demand for effective contraception methods, the growth outlook for this market is promising, with a projected market forecast indicating substantial expansion during the forecast period. The industry expansion is expected to be driven by advancements in technology, changing consumer behavior, and favorable regulations. The current Implantable Contraceptive Drug Eluting Devices market size is approximately $1.4 billion, with an expected growth rate of 7.5% CAGR during the forecast period.

Loading chart…

Key forces shaping the Implantable Contraceptive Drug Eluting Devices industry include technology shifts, such as the development of new implant materials and designs, regulations, such as changes in government policies and guidelines, and consumer behavior, such as increasing awareness and demand for effective and safe contraceptive methods. The largest region for Implantable Contraceptive Drug Eluting Devices is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing demand for contraceptive devices and growing healthcare infrastructure. As the market continues to evolve, it is essential for industry players to stay informed about the latest trends, competitive intensity, and supply-chain dynamics to remain competitive and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	4.32 billion
Revenue forecast in 2033	7.53 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; AbbVie; CooperSurgical; Egemen International; ERENLER MEDIKAL; Gyneas; Laboratoire CCD; Medical Engineering Corporation; Melbea; Meril Life Sciences; Mona Lisa; Pregna International; Prosan International; Rongbo Medical; SMB Corporation of India
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Implantable Contraceptive Drug Eluting Devices market is poised for significant growth, driven by increasing demand for long-acting reversible contraceptives and advancements in drug eluting technology. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Rising awareness about contraceptive options and growing preference for long-acting reversible contraceptives are driving the growth of the Implantable Contraceptive Drug Eluting Devices market size

Technological advancements in drug delivery systems and the development of new implantable devices are further fueling the growth forecast of the Implantable Contraceptive Drug Eluting Devices market

Restraints2 items

High development costs and stringent regulatory requirements are restraining the growth of the Implantable Contraceptive Drug Eluting Devices market, affecting its overall market size

Limited awareness and availability of Implantable Contraceptive Drug Eluting Devices in low-income countries are also hindering market growth, impacting the global growth forecast

Opportunities2 items

Increasing investments in research and development and collaborations between pharmaceutical companies and medical device manufacturers are creating opportunities for innovation in the Implantable Contraceptive Drug Eluting Devices market

Growing demand for contraceptive services in emerging economies presents a significant opportunity for market players to expand their presence and drive the growth forecast of the Implantable Contraceptive Drug Eluting Devices market

Challenges2 items

Ensuring patient safety and managing adverse effects associated with Implantable Contraceptive Drug Eluting Devices are significant challenges that market players must address to maintain a positive growth forecast

Navigating competitive landscapes and differentiating products in a crowded Implantable Contraceptive Drug Eluting Devices market are also key challenges that companies must overcome to achieve a significant market size

Market Segmentation

Loading chart…

The Application segment of the Implantable Contraceptive Drug Eluting Devices market refers to the various uses of these devices in preventing unwanted pregnancies. This segment is crucial in understanding the Implantable Contraceptive Drug Eluting Devices segmentation as it highlights the different areas where these devices are applied, such as hormonal implants and non-hormonal implants. The application segment contributes significantly to the overall market size, with a substantial portion of the market catering to the demand for effective and convenient contraceptive methods.

The Types segment of the Implantable Contraceptive Drug Eluting Devices market is further divided into subtypes, including intrauterine devices (IUDs) and subdermal implants. This segmentation is essential in analyzing the market taxonomy, as it provides insights into the specific types of devices that are in demand. The types segment plays a vital role in determining the overall market size, with each subtype contributing to the growth of the Implantable Contraceptive Drug Eluting Devices market. Understanding these subtypes is crucial for industry players to develop targeted strategies and products.

Implantable Contraceptive Drug Eluting Devices Segmentation Breakdown6 items

Application

Subcutaneously

Uterus

Types

Non-biodegradable

Biodegradable

Regional Insights

Loading chart…

The Implantable Contraceptive Drug Eluting Devices market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 35% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of contraceptive methods, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include high ecosystem maturity, established infrastructure, and growing demographics. In Europe, drivers include supportive policies, increasing awareness about contraceptive options, and a mature healthcare system. Asia Pacific is driven by large demographics, increasing adoption of modern contraceptive methods, and growing investments in healthcare. Latin America and Middle East & Africa are driven by improving infrastructure, increasing awareness, and favorable policies.

The regional forecast indicates that Asia Pacific will experience significant growth, driven by emerging economies and increasing demand for contraceptive methods. The Implantable Contraceptive Drug Eluting Devices market is expected to grow steadily, with all regions contributing to the growth, albeit at different rates. Understanding the regional dynamics and key drivers is crucial for stakeholders to capitalize on the growth opportunities in the Implantable Contraceptive Drug Eluting Devices market.

Competitive Landscape

The Implantable Contraceptive Drug Eluting Devices market is moderately consolidated, with a mix of global players and local companies competing on pricing, distribution, product innovation, certifications, and regulatory approvals. The Implantable Contraceptive Drug Eluting Devices competitive landscape is driven by key competitive levers such as product innovation and regulatory approvals, which enable companies to differentiate themselves and expand their market share. Global players dominate the market, but local companies are also present, particularly in emerging economies.

Companies in this market employ various strategies, including M&A, partnerships, product launches, expansion, R&D, and localization, to stay competitive. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To mitigate these risks, companies focus on strategic initiatives such as regional expansion, innovation pipeline, and local manufacturing.

Bayer: regional expansion

AbbVie: innovation pipeline

CooperSurgical: premium pricing

Egemen International: local manufacturing

ERENLER MEDIKAL: OEM tie-ups

Gyneas: vertical integration

Key Implantable Contraceptive Drug Eluting Devices Companies15 items

Bayer

AbbVie

CooperSurgical

Egemen International

ERENLER MEDIKAL

Gyneas

Laboratoire CCD

Medical Engineering Corporation

Melbea

Meril Life Sciences

Mona Lisa

Pregna International

Prosan International

Rongbo Medical

SMB Corporation of India

Market Ecosystem

The Implantable Contraceptive Drug Eluting Devices ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of these devices, with each segment influencing the overall Implantable Contraceptive Drug Eluting Devices ecosystem. The ecosystem's boundaries are defined by the interactions between these segments, from raw material suppliers to end users, with each player contributing to the creation and delivery of these devices.

Raw material suppliers — providing key components

OEMs / manufacturers — designing and producing devices

Technology providers — developing underlying technologies

System integrators / EPCs — integrating devices into healthcare systems

Distributors / channel partners — delivering devices to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — healthcare providers and patients

The flow of value through the ecosystem is influenced by control points, such as regulatory approvals and reimbursement policies, which can impact adoption rates. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem's functioning. Furthermore, switching costs, partnerships, and interoperability requirements can influence the relationships between ecosystem participants. As the ecosystem differs by region, due to varying regulatory frameworks and healthcare systems, understanding these regional nuances is crucial for navigating the value chain analysis of Implantable Contraceptive Drug Eluting Devices.

Recent Industry Insights

The Implantable Contraceptive Drug Eluting Devices industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between pharmaceutical companies and medical device manufacturers, have led to the creation of innovative products. Notable mergers and acquisitions have also taken place, with companies like Medtronic and Bayer expanding their portfolios in the implantable contraceptive market. Furthermore, there have been several product launches, including the introduction of new drug-eluting intrauterine devices. Regulatory changes, such as the FDA's approval of new contraceptive devices, have also impacted the industry. These developments indicate a shift in consumer trends towards more convenient and effective contraceptive options, driving growth in the Implantable Contraceptive Drug Eluting Devices market.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Implantable Contraceptive Drug Eluting Devices market outlook is that it presents a highly attractive opportunity for growth, driven by increasing demand for effective and convenient contraceptive solutions. The competitive intensity is moderate, with a few key players dominating the market, but innovation in technology and materials is expected to drive long-term growth.

The long-term outlook for the Implantable Contraceptive Drug Eluting Devices market is positive, with the innovation landscape expected to play a crucial role in shaping the industry. However, the demand–supply balance may be affected by regulatory factors and key risk factors such as product safety and efficacy concerns. Overall, the market is poised for significant growth, and stakeholders should monitor the Implantable Contraceptive Drug Eluting Devices market outlook closely to capitalize on emerging opportunities.

12 items

1. Executive Summary

2. Implantable Contraceptive Drug Eluting Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Implantable Contraceptive Drug Eluting Devices Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Implantable Contraceptive Drug Eluting Devices Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Implantable Contraceptive Drug Eluting Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Implantable Contraceptive Drug Eluting Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Implantable Contraceptive Drug Eluting Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Implantable Contraceptive Drug Eluting Devices Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Implantable Contraceptive Drug Eluting Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Implantable Contraceptive Drug Eluting Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Implantable Contraceptive Drug Eluting Devices Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Implantable Contraceptive Drug Eluting Devices Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Implantable Contraceptive Drug Eluting Devices Market Competition by Key Manufacturers

9.1. Global Implantable Contraceptive Drug Eluting Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Implantable Contraceptive Drug Eluting Devices: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bayer

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. AbbVie

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CooperSurgical

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Egemen International

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. ERENLER MEDIKAL

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Gyneas

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Laboratoire CCD

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Medical Engineering Corporation

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Melbea

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Meril Life Sciences

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Mona Lisa

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Pregna International

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Prosan International

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Rongbo Medical

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. SMB Corporation of India

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Implantable Contraceptive Drug Eluting Devices Market

Figure 4: Global Implantable Contraceptive Drug Eluting Devices Market: Drivers

Figure 5: Global Implantable Contraceptive Drug Eluting Devices Market: Challenges

Figure 6: Global Implantable Contraceptive Drug Eluting Devices Market: Trends

Figure 7: Global Implantable Contraceptive Drug Eluting Devices Market: Opportunity

Figure 8: Global Implantable Contraceptive Drug Eluting Devices Market: Restraint

Figure 9: Global Implantable Contraceptive Drug Eluting Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Implantable Contraceptive Drug Eluting Devices Market Value (USD Million) By Region

Figure 19: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Implantable Contraceptive Drug Eluting Devices Market Value (USD Million) By Region

Figure 27: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By: Regions (2032)

Figure 28: Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) By Region

Figure 29: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Implantable Contraceptive Drug Eluting Devices Market Value (USD Million) By Region

Figure 37: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By: Regions (2032)

Figure 38: Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) By Region

Figure 39: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Implantable Contraceptive Drug Eluting Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Implantable Contraceptive Drug Eluting Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Implantable Contraceptive Drug Eluting Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Implantable Contraceptive Drug Eluting Devices Market Value (USD Million) By Region

Table 14: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) By Region

Table 31: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Implantable Contraceptive Drug Eluting Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Implantable Contraceptive Drug Eluting Devices Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Implantable Contraceptive Drug Eluting Devices Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bayer Basic Information And Sales Area

Table 52: Bayer. Products Portfolio

Table 53: AbbVie Basic Information And Sales Area

Table 54: AbbVie. Products Portfolio

Table 55: CooperSurgical Basic Information And Sales Area

Table 56: CooperSurgical. Products Portfolio

Table 57: Egemen International Basic Information And Sales Area

Table 58: Egemen International. Products Portfolio

Table 59: ERENLER MEDIKAL Basic Information And Sales Area

Table 60: ERENLER MEDIKAL. Products Portfolio

Table 61: Gyneas Basic Information And Sales Area

Table 62: Gyneas. Products Portfolio

Table 63: Laboratoire CCD Basic Information And Sales Area

Table 64: Laboratoire CCD. Products Portfolio

Table 65: Medical Engineering Corporation Basic Information And Sales Area

Table 66: Medical Engineering Corporation. Products Portfolio

Table 67: Melbea Basic Information And Sales Area

Table 68: Melbea. Products Portfolio

Table 69: Meril Life Sciences Basic Information And Sales Area

Table 70: Meril Life Sciences. Products Portfolio

Table 71: Mona Lisa Basic Information And Sales Area

Table 72: Mona Lisa. Products Portfolio

Table 73: Pregna International Basic Information And Sales Area

Table 74: Pregna International. Products Portfolio

Table 75: Prosan International Basic Information And Sales Area

Table 76: Prosan International. Products Portfolio

Table 77: Rongbo Medical Basic Information And Sales Area

Table 78: Rongbo Medical. Products Portfolio

Table 79: SMB Corporation of India Basic Information And Sales Area

Table 80: SMB Corporation of India. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Implantable Contraceptive Drug Eluting Devices Market Value (USD Million) By Region

Table 90: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Application

Table 93: North America Market Value (USD Million) (2025-2032) By Types

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Types

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Types

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 106: Global Implantable Contraceptive Drug Eluting Devices Market Volume (K) By Region

Table 107: Global Implantable Contraceptive Drug Eluting Devices Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Application

Table 110: North America Market Volume (K) (2025-2032) By Types

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Types

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Types

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Implantable Contraceptive Drug Eluting Devices Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.32 billion
Revenue forecast in 2033	7.53 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; AbbVie; CooperSurgical; Egemen International; ERENLER MEDIKAL; Gyneas; Laboratoire CCD; Medical Engineering Corporation; Melbea; Meril Life Sciences; Mona Lisa; Pregna International; Prosan International; Rongbo Medical; SMB Corporation of India
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High development costs and stringent regulatory requirements are restraining the growth of the Implantable Contraceptive Drug Eluting Devices market, affecting its overall market size

Limited awareness and availability of Implantable Contraceptive Drug Eluting Devices in low-income countries are also hindering market growth, impacting the global growth forecast

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Implantable Contraceptive Drug Eluting Devices Segmentation Breakdown6 items

Application

Subcutaneously

Uterus

Types

Non-biodegradable

Biodegradable

Regional Insights

Loading chart…

Competitive Landscape

Bayer: regional expansion

AbbVie: innovation pipeline

CooperSurgical: premium pricing

Egemen International: local manufacturing

ERENLER MEDIKAL: OEM tie-ups

Gyneas: vertical integration

Key Implantable Contraceptive Drug Eluting Devices Companies15 items

Bayer

AbbVie

CooperSurgical

Egemen International

ERENLER MEDIKAL

Gyneas

Laboratoire CCD

Medical Engineering Corporation

Melbea

Meril Life Sciences

Mona Lisa

Pregna International

Prosan International

Rongbo Medical

SMB Corporation of India

Market Ecosystem

Raw material suppliers — providing key components

OEMs / manufacturers — designing and producing devices

Technology providers — developing underlying technologies

System integrators / EPCs — integrating devices into healthcare systems

Distributors / channel partners — delivering devices to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — healthcare providers and patients

Recent Industry Insights

Analyst Overview

Table of Contents